Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A three-way crossover, Phase III, pharmacokinetic study evaluating the bioavailability of RHB-105 actives versus the comparator in healthy volunteers.

Trial Profile

A three-way crossover, Phase III, pharmacokinetic study evaluating the bioavailability of RHB-105 actives versus the comparator in healthy volunteers.

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amoxicillin/omeprazole/rifabutin (Primary)
  • Indications Helicobacter pylori infections
  • Focus Pharmacokinetics; Registrational
  • Sponsors RedHill Biopharma
  • Most Recent Events

    • 01 Aug 2023 According to a RedHill Biopharma media release, Gaelan Medical received marketing approval from the United Arab Emirates (UAE) Ministry of Health for Talicia (omeprazole magnesium, amoxicillin and rifabutin).
    • 04 Nov 2019 According to an RedHill Biopharma media release, the company will host an Investor and Analyst day on November 22, 2019 in New York to review launch plans for Talicia and provide an overview of the Company's commercial operations.
    • 04 Nov 2019 According to an RedHill Biopharma media release, the company announced that the U.S. Food and Drug Administration (FDA) has approved Talicia(omeprazole magnesium, amoxicillin and rifabutin) delayed-release capsules 10 mg1/250 mg/12.5 mg for the treatment of Helicobacter pylori (H. pylori) infection in adults.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top